TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01790841

Intervention type: DEVICE
Intervention: Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego

Intervention type: DEVICE
Intervention: Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego
Study: NCT00673036

Intervention type: OTHER
Intervention: Blood sample
Description: 60 ml of whole blood
Study: NCT02442089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Call
Description: Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
Study: NCT01511783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
Study: NCT02309151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Description: Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
Study: NCT00017368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03523611

Intervention type: PROCEDURE
Intervention: Lung Resection
Description: Lung resection surgery
Study: NCT03845140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT 50 mg/kg
Description: Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT 50 mg/kg
Description: Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT 50 mg/kg
Description: Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT 50 mg/kg
Description: Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biltricide®
Description: Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT 60 mg/kg
Description: Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.
Study: NCT00754364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
Study: NCT01422551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management
Description: 10 weekly 2-hour sessions of group-based cognitive behavioral stress management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a psycho-educational control
Description: a single-day psycho-educational seminar
Study: NCT01644448

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous Human Platelet Lysate
Description: Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Therapy
Description: Topical Applications as directed by the investigator
Study: NCT02015455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidemiologic benchmarks included in lumbar imaging reports
Description: Epidemiologic benchmarks inserted into lumbar imaging reports
Study: NCT04427059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) block
Description: The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Port-Site Infiltration (PSI)
Description: The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
Study: NCT04656496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOURISH-T+
Description: NOURISH-T+ (Nourishing Our Understanding of Role Modeling to Improve Support and Healthy - Transitions) is a 6 session, psychoeducational program designed to teach parents of childhood cancer survivors with overweight/obesity knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief NOURISH-T+
Description: Enhanced Usual Care (or Brief NOURISH-T+) is an abbreviated version of the full NOURISH-T+ intervention in which parents are engaged in a one-time information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
Study: NCT04032613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular Access Navigation and Education Quality Improvement Program
Description: A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
Study: NCT04855838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training
Description: The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
Study: NCT04180033

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Colonoscopy surveillance
Description: Participants will be asked to undergo a first colonoscopy surveillance.
Study: NCT03918369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with intracorporeal anastomosis.
Description: Intracorporeal anastomosis group The laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis. In this procedure, intracorporeal division of the mesoileum and transverse colon is performed, as shown in the animation. The ileum and transverse colon are divided with the Endopath® Echelon Flex ™ 60 stapler. The specimen is inserted in a plastic bag. Side-to-side isoperistaltic mechanical anastomosis is performed using the same endostapler. A running suture is performed of the mechanical suture orifice, with another reinforcing suture with Monocryl ™ (poliglecaprone 25) or with STRATAFIX ™ Spiral Knotless barbed suture. The specimen is extracted through a Pfannestiel minilaparotomy (3.5-4 cm) Wound Protector

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right hemicolectomy with extracorporeal anastomosis.
Description: Laparoscopic right hemicolectomy with extracorporeal anastomosis with the technical features of each center
Study: NCT04241107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic repair of Uterine niche
Description: Repair of uterine niche through Laparoscopic approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal repair of Uterine niche
Description: Repair of uterine niche through Transvaginal approach.
Study: NCT00431353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: 5mg/kg iv bid for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: 900mg po bid for 21 days
Study: NCT00690053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of HX-4
Description: In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
Study: NCT02410616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended CBT
Description: Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
Study: NCT00830089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivicaine 0.25%
Description: 40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
Study: NCT05584995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BUAL group
Description: Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum.
Study: NCT01758497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: 30 ml 0.5% ropivacaine, beneath the fascia iliaca

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fascia Iliaca compartment block
Description: 30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
Study: NCT03451981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical debridement and chemical decontamination
Description: mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: mechanical debridement and chemical decontamination
Description: mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical debridement and chemical decontamination
Description: mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air Powder
Description: mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
Study: NCT02735031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 6 weeks treatment with exenatide on top of insulin treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks treatment with placebo on top of insulin treatment
Study: NCT00259935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: topotecan
Study: NCT03846869

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: major cations
Description: blood sample
Study: NCT03017092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet-guided tobacco intervention
Description: This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
Study: NCT01753349

Intervention type: BIOLOGICAL
Intervention: Botulinum toxin type A
Description: Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
Study: NCT01653275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
Study: NCT02376686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
Study: NCT01249131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
Study: NCT02659943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3